Detailed Mechanism of Action: Selank Component
Selank is a synthetic stabilized analog of the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg). The four-amino-acid core of tuftsin is extended with Pro-Gly-Pro, a sequence derived from the neural peptide glyprolines, which dramatically improves its metabolic stability and CNS penetration. When researchers use this blend, they gain access to Selank’s interaction with the GABA-A receptor complex, modulating benzodiazepine binding sites without the tolerance or dependence issues associated with classical anxiolytics.
Selank’s anxiolytic mechanism is believed to involve upregulation of the enzyme methionine aminopeptidase, which processes enkephalins and modulates the endogenous opioid system. Simultaneously, Selank increases expression of BDNF in hippocampal tissue and modulates serotonin transporter function. Research indicates Selank also suppresses IL-6 and increases IL-2 production, linking neurological and immunological research applications in a single compound. These multi-target properties make the blend particularly valuable for experimental designs examining the gut-brain-immune axis.
At the molecular level, Selank has been shown to interact with the trace amine-associated receptor 1 (TAAR1) system, which regulates monoamine signaling across dopamine, serotonin, and norepinephrine pathways. This explains the wide-spectrum anxiolytic and cognitive-enhancing effects observed in animal models. For an in-depth comparison of Selank with related compounds, see our Semax vs Selank nootropic comparison guide.
Detailed Mechanism of Action: Semax Component
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) sequence with the Pro-Gly-Pro C-terminal extension identical to that of Selank, conferring similar metabolic stability. The ACTH fragment region (Phe-Pro) is critical for melanocortin receptor interactions, but Semax’s primary CNS effects appear to be mediated through direct regulation of neurotrophic factor expression rather than through melanocortin signaling alone.
Published research demonstrates that Semax administration at micromolar concentrations produces robust upregulation of BDNF mRNA in the hippocampus and cortex within hours of exposure. This BDNF surge activates TrkB receptors, triggering MAPK/ERK and PI3K/Akt pathways that promote neuronal survival, synaptic plasticity, and long-term potentiation. Researchers using this blend gain access to these BDNF-mediated effects alongside Selank’s complementary mechanisms. NGF upregulation by Semax additionally supports research into cholinergic neuron maintenance and Alzheimer’s disease models.
Semax has demonstrated neuroprotection in middle cerebral artery occlusion (MCAO) models, reducing infarct volume by 30–45% in rat studies at doses of 50–200 μg/kg. The compound activates HIF-1α, upregulates antioxidant enzymes (SOD, catalase), and reduces inflammatory cytokine cascades (TNF-α, IL-1β) in ischemic tissue. This neuroprotective profile makes this formulation particularly relevant for stroke, TBI, and excitotoxicity research models.
Published Research Supporting This Blend
Selank’s anxiolytic and cognitive effects have been documented in multiple peer-reviewed studies. A key 2001 study by Semenova et al. demonstrated that Selank at 0.3–1.0 mg/kg produced anxiolytic effects in the elevated plus maze comparable to diazepam at 1 mg/kg, without sedation or muscle relaxation. Research by Uchakina et al. documented Selank’s immunomodulatory effects, showing significant normalization of IL-6 and IL-2 levels in patients with anxiety disorders in a clinical setting. See: Selank anxiolytic and immunomodulation research on PubMed.
For Semax, the landmark BDNF upregulation research by Dolotov et al. (2006) established that a single intranasal Semax administration increases hippocampal BDNF by 140% within 24 hours. A 2003 clinical study by Gusev and Skvortsova demonstrated Semax’s neuroprotective effects in acute ischemic stroke patients, with the Semax group showing significantly better neurological outcomes at 30 days (p < 0.05) versus placebo. See: Semax BDNF upregulation research on PubMed. Researchers working with this blend can leverage this established scientific literature to design experiments building on these foundations.
The synergistic potential of combining Selank and Semax in a single co-formulated preparation is supported by their complementary target profiles: Selank acts primarily through GABA, serotonin, and immune pathways, while Semax targets neurotrophic factor expression, melanocortin receptors, and HIF-1α neuroprotection. The 50:50 ratio in this blend reflects optimal dosing symmetry for experimental designs requiring balanced GABAergic/neurotrophic co-stimulation. See our peptide stacking research guide for more on combining neurological peptides.
Buy Selank Semax Blend vs Alternatives: Research Comparison
| Feature | Selank+Semax Blend | Selank Alone | Semax Alone | Adamax (modified Semax) |
|---|
| Primary Target | Dual anxiolytic + neurotrophic | GABAergic / immune | BDNF / NGF / neuroprotection | Neurotrophic only (extended-duration) |
| Receptor Profile | GABA-A, TrkB, TAAR1, MC4R | GABA-A, TAAR1, serotonin | TrkB, MC4R, HIF-1α | MC4R, TrkB |
| Research Breadth | Highest — multi-pathway | Moderate — anxiety focus | Moderate — cognitive focus | Focused — single-pathway |
| BDNF Upregulation | Yes (Semax component) | Indirect / mild | Direct / strong (+140%) | Yes (Semax analog) |
| Anxiolytic Effect | Yes (Selank component) | Primary mechanism | Indirect / mild | No |
| Immunomodulation | Yes (Selank component) | Strong — IL-2/IL-6 | Mild | No |
| Neuroprotection | Yes (Semax component) | Mild | Strong — MCAO models | Yes (Semax pathway) |
| Experimental Value | Highest — single vial dual pathway | Focused anxiety studies | Focused cognitive studies | Extended half-life, single pathway |
For researchers comparing nootropic peptide options, our dedicated article on Semax vs Selank: nootropic research comparison provides deeper analysis of individual compound profiles before selecting this blend. Additionally, our complete guide to research peptides contextualizes these compounds within the broader neurological peptide landscape. Researchers investigating an extended-duration Semax analog rather than a two-peptide combination should see the Adamax product page — Adamax is a chemically modified Semax — N-Acetyl Semax Amidate (Ac-MEHFPGPAG-NH2), capped at both termini for extended half-life — distinct from this blend.
Reconstitution & Handling Protocol
This blend is supplied as a white to off-white lyophilized powder in a sealed amber vial. Prior to any experimental use, the peptide blend must be reconstituted with bacteriostatic water (BAC water) using sterile technique. The 0.9% benzyl alcohol in BAC water provides antimicrobial preservation for up to 28 days post-reconstitution when stored at 4°C in darkness.
Standard reconstitution protocol: Allow the vial to equilibrate to room temperature for 15 minutes before opening. Add BAC water slowly to the interior wall of the vial — never inject directly onto the lyophilized cake. Gently swirl (never vortex) until the powder dissolves completely, yielding a clear, colorless solution. For precise reconstitution volumes based on your target research concentration, use our free peptide reconstitution calculator. For step-by-step guidance, see our complete peptide reconstitution guide.
Reconstitution volume determines your working concentration, and the two vial sizes carry different total peptide loads and different component ratios. Worked examples for each:
| Vial | 10MG (5mg Selank + 5mg Semax) | 40MG (30mg Selank + 10mg Semax) |
| Add 2.5 mL BAC water | 4 mg/mL total — 2 mg/mL each | 16 mg/mL total — 12 mg/mL Selank + 4 mg/mL Semax |
| Add 2 mL BAC water | 5 mg/mL total — 2.5 mg/mL each | 20 mg/mL total — 15 mg/mL Selank + 5 mg/mL Semax |
| Add 1 mL BAC water | 10 mg/mL total — 5 mg/mL each | 40 mg/mL total — 30 mg/mL Selank + 10 mg/mL Semax |
Note that the 40MG vial is not simply a larger 50:50 blend — its 75:25 ratio means Selank concentration rises faster than Semax at any given reconstitution volume. Plan the volume around whichever component your protocol is dose-limited by. Always prepare the minimum volume needed for your experimental series, and aliquot into smaller volumes if extended storage is required to minimize freeze-thaw cycles once reconstituted.
Storage & Stability Guidelines
This lyophilized peptide blend is highly stable when stored correctly. Lyophilized (unreconstituted) vials should be stored at -20°C in a frost-free freezer, protected from light and moisture. Under these conditions, stability is maintained for 24+ months from the manufacture date. Short-term storage at 4°C (refrigerator) for up to 3 months is acceptable for lyophilized material if -20°C storage is temporarily unavailable.
Once reconstituted, the blend solution should be used within 28 days when stored at 4°C in darkness. Do not freeze reconstituted peptide solutions — ice crystal formation disrupts peptide tertiary structure. Aliquoting into single-use volumes before the first freeze minimizes degradation from repeated freeze-thaw cycles. Discard any reconstituted solution showing visible particulates, cloudiness, or discoloration. For comprehensive storage best practices, see our peptide storage guide and our guide on how to tell if a peptide has degraded.
Both Selank and Semax contain the Pro-Gly-Pro stabilizing motif, which confers superior metabolic resistance compared to parent peptides tuftsin and ACTH(4-7). This structural feature gives this peptide blend excellent shelf stability relative to many other research peptides, making it particularly suitable for studies requiring consistent concentration over extended experimental timelines.
Certificate of Analysis
Every vial of the Selank+Semax Blend from PSPeptides ships with a batch-specific Certificate of Analysis (COA). The COA documents purity verification via high-performance liquid chromatography (HPLC) with UV detection and identity confirmation via mass spectrometry (MS). The HPLC chromatogram confirms purity ≥99% by peak area analysis for both Selank and Semax components. Mass spectrometry confirms the molecular weight of each peptide within ±0.5 Da of theoretical values.
PSPeptides performs all purity testing through independent third-party laboratories — not in-house — ensuring unbiased verification of every batch. COAs are included in the package and are also available for download on the product page or by contacting our support team. Current batch documents are available directly: 40MG HPLC certificate of analysis (batch NAD-0036037, with endotoxin, heavy metals and sterility reports), and the 10MG HPLC certificate of analysis (batch PSP-0029116). To learn how to interpret your COA data and verify you are receiving authentic, high-purity research peptides, see our guide on how to read a peptide COA. Understanding COA data is essential quality control for any researcher working with this blend or any other research peptide.
Why Researchers Choose PSPeptides to Buy Selank Semax Blend
- US Manufactured: All peptides including this blend are synthesized in US-based cGMP-compliant facilities under strict quality oversight
- Third-Party Tested: Independent HPLC and mass spectrometry verification on every single batch — not just spot checks
- Fast Shipping: Free UPS 2nd Day Air on orders over $200, same-day dispatch on orders placed before 2 PM EST
- Flexible Payments: Credit cards, Afterpay, Klarna, Apple Pay, and Google Pay accepted
- 7-Day Support: Dedicated customer service available 7 days a week via email
- Transparent COAs: Batch-specific third-party verified COAs shipped with every order
For researchers evaluating suppliers before choosing a supplier, our guides on how to choose a research peptide supplier and best peptide companies in 2026 provide comprehensive comparison frameworks. See also our dedicated research peptides legal status guide for 2026.
Frequently Asked Questions About Buy Selank Semax Blend
What makes the Selank+Semax blend unique compared to using each peptide separately?
The blend provides simultaneous access to two complementary neurological pathways in a single vial: Selank’s GABAergic anxiolytic and immunomodulatory mechanisms alongside Semax’s BDNF/NGF neurotrophic upregulation and neuroprotective properties. This dual-target profile enables experimental designs that would otherwise require two separate reconstituted solutions, reducing experimental complexity and ensuring consistent molar ratios across research sessions. The 50:50 blend also allows researchers to study potential synergistic or antagonistic interactions between these pathways.
How should I store this blend after reconstitution?
After reconstitution with bacteriostatic water, store the peptide solution at 4°C (refrigerator temperature) in darkness, in a sealed vial to prevent contamination and evaporation. Reconstituted solution is stable for up to 28 days under these conditions. Do not freeze reconstituted peptide solutions, as this causes ice crystal formation that can damage peptide structure. If you need to store beyond 28 days, consult your lab’s lyophilization protocols.
Is this blend suitable for intranasal administration research?
Both Selank and Semax have been investigated via intranasal routes in published research, with Semax in particular showing robust intranasal bioavailability in CNS models due to olfactory nerve transport. The blend, when reconstituted, is compatible with intranasal delivery protocols used in published Semax and Selank studies. Researchers should design their intranasal protocols based on peer-reviewed literature for each component and ensure appropriate sterile technique and vehicle selection for their specific experimental model.
How does PSPeptides verify the purity of the blend components separately?
PSPeptides independently tests both the Selank and Semax fractions before blending, ensuring each component meets ≥99% purity specifications. The final blend COA then documents the blended product’s combined HPLC profile, confirming both peptide peaks are present at the expected retention times and that no degradation products or synthesis impurities exceed trace levels. This multi-step quality control process means researchers using this blend can be confident that both the individual component purities and the final formulation meet rigorous research standards.
What is the half-life of Selank and Semax in biological systems?
The Pro-Gly-Pro C-terminal extension on both peptides significantly extends their biological half-life compared to parent structures. Selank has a plasma half-life of approximately 3–5 minutes for the core tuftsin sequence, but the stabilized Selank analog demonstrates substantially prolonged activity in CNS tissue. Semax similarly has an intranasal half-life estimated at 20–30 minutes with activity windows extending 3–8 hours in neurotrophic factor assays. For a comprehensive reference on research peptide half-life data, see our peptide half-life chart.
How is the Selank+Semax Blend different from Adamax?
The Selank+Semax Blend is a combination of two distinct peptides (Selank + Semax) in a single research vial, delivering both the GABAergic anxiolytic pathway (Selank) and the MC4R/BDNF cognitive pathway (Semax) in one preparation. Adamax is a single chemically modified peptide — N-Acetyl Semax Amidate (Ac-MEHFPGPAG-NH2), a Semax analog capped at both termini for extended half-life, but not a combination. Choose the Blend for dual-pathway research protocols; choose Adamax for extended-duration single-pathway research on the Semax MC4R/BDNF axis.
Peptide Half-Life and Dosing Considerations for Research
Understanding the pharmacokinetic profiles of both components is essential for experimental design with this combination. The Pro-Gly-Pro stabilization motif shared by both Selank and Semax protects the peptides from rapid degradation by brain endopeptidases, providing researchers with more predictable activity windows compared to unstabilized parent peptides. This structural stability is one reason this blend has become a preferred dual-nootropic research tool in neurological studies.
For subcutaneous delivery protocols commonly used with this peptide combination in rodent models, researchers typically work with concentrations of 0.1–1.0 mg/mL per component, with volumes calculated to deliver individual peptide doses equivalent to published single-compound studies. Our subcutaneous vs intramuscular peptide injection guide details the technical considerations for each route in preclinical research. For general peptide dosing calculation tools, the peptide dosage calculator guide walks through each step of the calculation process.
Neurological Research Applications in 2026
The landscape of neurological peptide research has expanded considerably in 2026, with this blend positioning itself as a key compound of interest across multiple active research domains. Anxiety disorder models, cognitive decline research, traumatic brain injury protocols, and post-stroke neuroregeneration studies have all cited Selank or Semax components in recent literature. Researchers looking for established, well-characterized nootropic compounds with decades of published safety and efficacy data in preclinical models consistently include this blend in their research toolkit.
Interest in dual-mechanism peptide combinations has grown as researchers recognize that neurological disorders rarely involve single pathway dysfunction. The blend’s simultaneous targeting of neurotrophic factors, GABAergic tone, and immune modulation reflects the current understanding of the interconnected nature of anxiety, cognitive function, and neuroinflammation. For those researching peptides specifically for neurological applications, our guides on peptides for sleep and recovery and peptides for immune support research provide complementary reading alongside the Selank+Semax Blend literature.
As interest in research peptides continues to evolve in 2026, PSPeptides remains committed to providing high-quality Selank+Semax Blend formulations with full third-party testing documentation. Researchers can access our complete neurological peptide catalog and supporting resources at PSPeptides.com, where every order is backed by transparent COA data and US-based manufacturing standards.
Related Research Resources
All PSPeptides products including this blend are sold exclusively for in vitro laboratory and preclinical research use only. Not intended for human consumption, veterinary use, or therapeutic application. For research use only.
Made & Shipped
